医药行业深度研究：原料药板块Q1利润同比快速增长，关注行业供需改善

Investment Rating - The report indicates a positive outlook for the pharmaceutical raw materials sector, highlighting a significant profit growth in Q1 and an expected improvement in industry supply and demand dynamics [3][4]. Core Insights - The pharmaceutical raw materials sector experienced a revenue of CNY 1176.77 billion in 2024, a year-on-year increase of 6.74%, with a net profit of CNY 150.46 billion, reflecting a growth of 27.89% [3][4][21]. - In Q1 2025, the sector reported a revenue of CNY 295.46 billion, a slight decline of 0.48% year-on-year, but a net profit increase of 20.87% to CNY 45.62 billion [3][4][21]. - The profit growth is attributed to several factors, including a low base in H2 2023, the end of inventory destocking by global downstream manufacturers, and improved cost management [3][4][21][23]. Summary by Sections Q1 Profit Growth and Margin Improvement - The raw materials sector's revenue remained stable year-on-year in Q1 2025, with a slight increase of 5.77% quarter-on-quarter. The net profit and non-recurring net profit saw significant year-on-year growth of 20.87% and 21.98%, respectively [3][4][21][23]. - The gross margin for 2024 was 38.00%, up 1.58 percentage points year-on-year, while the net margin improved to 12.79%, an increase of 4.97 percentage points [4][24][25]. Industry Concentration and Top Companies - The top 10 companies in the raw materials sector contributed over 73.33% of total revenue in 2024, with significant contributions from companies like New and Cheng and Prolo Pharmaceuticals [31][33]. - In Q1 2025, the top 10 companies accounted for 73.19% of total revenue, with New and Cheng alone contributing over 10% [33][34]. Valuation and Construction Projects - The sector's valuation remains at historical lows, with a PE ratio of 30.26 times at the end of 2024, which is in the 14% historical percentile [5][42]. - As of Q1 2025, the construction projects in the sector totaled CNY 163.57 billion, a decrease of 4.31% year-on-year, indicating a slowdown in capacity expansion [9][44]. Investment Recommendations - The report suggests focusing on companies with strong performance in the formulation and CDMO sectors, such as Aorite and Prolo Pharmaceuticals, as well as those with significant new product pipelines like Tonghe Pharmaceuticals [10][6][10].